Literature DB >> 33491309

Pharmacogenomics of Medication-Induced Weight Gain and Antiobesity Medications.

Sneha Singh1,2, Maria L Ricardo-Silgado1,2, Suzette J Bielinski3, Andres Acosta1,2.   

Abstract

Obesity is a chronic, multifactorial disease associated with a large number of comorbidities. The clinical management of obesity involves a stepwise integrated approach, beginning with behavioral and lifestyle modification, followed by antiobesity medications, endobariatric procedures, and bariatric surgery. Weight gain and subsequent obesity are common side effects of medications, such as prednisone or antipsychotics. In this era of precision medicine, it is essential to identify patients at the highest risk of weight gain as a result of medication use. Pharmacogenomics could play an important role in obesity management by optimizing use of antiobesity medications as well as minimizing adverse weight gain. This review aims to provide a comprehensive analysis of the current literature on the role of pharmacogenomics in obesity and medication-induced weight gain. In summary, there are more robust studies of medication associated with weight gain and pharmacogenomics, and more studies are needed to understand the role of pharmacogenomics in antiobesity medications.
© 2021 The Obesity Society.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33491309      PMCID: PMC8215694          DOI: 10.1002/oby.23068

Source DB:  PubMed          Journal:  Obesity (Silver Spring)        ISSN: 1930-7381            Impact factor:   5.002


  62 in total

1.  No evidence for a major role of polymorphisms during bupropion treatment.

Authors:  Jianfang Hu; David T Redden; Wade H Berrettini; Peter G Shields; Stephanie L Restine; Angela Pinto; Caryn Lerman; David B Allison
Journal:  Obesity (Silver Spring)       Date:  2006-11       Impact factor: 5.002

2.  The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity.

Authors:  A Flint; A Raben; A K Ersbøll; J J Holst; A Astrup
Journal:  Int J Obes Relat Metab Disord       Date:  2001-06

Review 3.  White Paper AGA: POWER - Practice Guide on Obesity and Weight Management, Education, and Resources.

Authors:  Andres Acosta; Sarah Streett; Mathew D Kroh; Lawrence J Cheskin; Katherine H Saunders; Marina Kurian; Marsha Schofield; Sarah E Barlow; Louis Aronne
Journal:  Clin Gastroenterol Hepatol       Date:  2017-02-27       Impact factor: 11.382

4.  Effects of SLC22A1 Polymorphisms on Metformin-Induced Reductions in Adiposity and Metformin Pharmacokinetics in Obese Children With Insulin Resistance.

Authors:  Wai Johnn Sam; Orsolya Roza; Yuen Yi Hon; Raul M Alfaro; Karim A Calis; James C Reynolds; Jack A Yanovski
Journal:  J Clin Pharmacol       Date:  2016-08-23       Impact factor: 3.126

5.  GRIK1 genotype moderates topiramate's effects on daily drinking level, expectations of alcohol's positive effects and desire to drink.

Authors:  Henry R Kranzler; Stephen Armeli; Richard Feinn; Howard Tennen; Joel Gelernter; Jonathan Covault
Journal:  Int J Neuropsychopharmacol       Date:  2014-04-30       Impact factor: 5.176

Review 6.  Weight gain and antidepressants.

Authors:  M Fava
Journal:  J Clin Psychiatry       Date:  2000       Impact factor: 4.384

7.  Allelic variant in the glucagon-like peptide 1 receptor gene associated with greater effect of liraglutide and exenatide on gastric emptying: A pilot pharmacogenetics study.

Authors:  V Chedid; P Vijayvargiya; P Carlson; K Van Malderen; A Acosta; A Zinsmeister; M Camilleri
Journal:  Neurogastroenterol Motil       Date:  2018-02-28       Impact factor: 3.598

8.  XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients.

Authors:  Jarl S Torgerson; Jonathan Hauptman; Mark N Boldrin; Lars Sjöström
Journal:  Diabetes Care       Date:  2004-01       Impact factor: 19.112

9.  Association of LEPR and ANKK1 Gene Polymorphisms with Weight Gain in Epilepsy Patients Receiving Valproic Acid.

Authors:  Hongliang Li; Xueding Wang; Yafang Zhou; Guanzhong Ni; Qibiao Su; Ziyi Chen; Zhuojia Chen; Jiali Li; Xinmeng Chen; Xiangyu Hou; Wen Xie; Shuang Xin; Liemin Zhou; Min Huang
Journal:  Int J Neuropsychopharmacol       Date:  2015-03-03       Impact factor: 5.176

Review 10.  Reward-Induced Eating: Therapeutic Approaches to Addressing Food Cravings.

Authors:  Candida J Rebello; Frank L Greenway
Journal:  Adv Ther       Date:  2016-10-07       Impact factor: 3.845

View more
  2 in total

1.  Resting Energy Expenditure and Body Composition in Children and Adolescents With Genetic, Hypothalamic, Medication-Induced or Multifactorial Severe Obesity.

Authors:  Ozair Abawi; Emma C Koster; Mila S Welling; Sanne C M Boeters; Elisabeth F C van Rossum; Mieke M van Haelst; Bibian van der Voorn; Cornelis J de Groot; Erica L T van den Akker
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-11       Impact factor: 6.055

2.  Association between CYP metabolizer phenotypes and selective serotonin reuptake inhibitors induced weight gain: a retrospective cohort study.

Authors:  Maria L Ricardo-Silgado; Sneha Singh; Lizeth Cifuentes; Paul A Decker; Daniel Gonzalez-Izundegui; Ann M Moyer; Maria D Hurtado; Michael Camilleri; Suzette J Bielinski; Andres Acosta
Journal:  BMC Med       Date:  2022-07-26       Impact factor: 11.150

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.